John Tsai, Novartis R&D chief
October 7, 2021 08:47 AM EDT
R&D

Em­bold­ened by a pos­i­tive PhI­II, No­var­tis steers a late-stage BTK in­hibitor in­to a piv­otal MS tri­al

John Carroll

Editor & Founder

No­var­tis is tak­ing a dig­i­tal turn at the up­com­ing ECTRIMS con­fer­ence with dozens of ab­stracts on its im­munol­o­gy drugs al­ready on the mar­ket. And no­tably …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times